MA
ORMP icon

MUFG Americas’s Oramed Pharmaceuticals ORMP Stock Holding History

MUFG Americas’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-834
Closed -$7K – 1374
2013
Q2 		$7K Buy
+834
New +$6.87K ﹤0.01% 1444

Other funds holding ORMP

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
HRIA
Haberer Registered Investment Advisor Cincinnati, Ohio $165M AUM 11.95% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MUFG Americas's ORMP Position: Q3 2013 in Review

MUFG Americas sold out of Oramed Pharmaceuticals (ORMP) in Q3 2013, closing a stake of 834 shares — an estimated $7K sold.

MUFG Americas first reported a position in ORMP in Q2 2013 and held it in 1 quarter. The position peaked at $7K in Q2 2013. 7 funds tracked by Wall St. Rank hold ORMP as of Q3 2013.

  • MUFG Americas reported no remaining Oramed Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • MUFG Americas sold 834 Oramed Pharmaceuticals shares in Q3 2013, an estimated $7K.
  • MUFG Americas first reported a position in Oramed Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • MUFG Americas's Oramed Pharmaceuticals position peaked at $7K in Q2 2013.
  • 7 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2013.

Based on MUFG Americas's 13F filing for Q3 2013, filed 8 Nov 2013.